Keyword: Alex Denner

After its Alzheimer's drug flop wiped out 30% of Biogen's market cap, the company is adding three new members to its board.

Ironwood may have avoided sparring with activists by introducing an R&D split-off, but its employees paid the price.

Ironwood’s activist investor likes what it’s seen recently from the drugmaker—so much so that it held off on pushing for a spot on the company's board.

Investors aren’t happy with the steps Allergan has taken to try to remedy its share-price slump—and they’re calling on outsiders to help stir things up.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Sanofi didn't just woo Bioverativ execs. It made a play with investor Alex Denner. The result? $85M for CEO John Cox and a 2018 EPS boost for Sanofi.